Your session is about to expire
Glimepiride vs Glipizide
Introduction
For patients with Type 2 diabetes, certain drugs that regulate the production and release of insulin can help manage blood sugar levels. Glimepiride and Glipizide are two such medications commonly prescribed for this condition. They each impact different aspects of pancreatic function but both aid in controlling blood glucose levels in patients with diabetes. Glimepiride is a sulfonylurea class drug which encourages the pancreas to produce more insulin while also increasing tissue sensitivity to insulin itself. On the other hand, Glipizide primarily stimulates beta cells within the pancreas to release more insulin. Both medications require caution during use as they can cause hypoglycemia (low blood sugar) if not properly monitored.
Glimepiride vs Glipizide Side By Side
| Attribute | Amaryl | Glucotrol |
|---|---|---|
| Brand Name | Amaryl | Glucotrol |
| Contraindications | Should not be used by patients with diabetic ketoacidosis or those allergic to sulfonylureas. Not to be used if taking bosentan. | Should not be used by patients with diabetic ketoacidosis or those allergic to sulfonylureas. Not to be used if taking bosentan. |
| Cost | For the brand name, about $125 to $170 for 30 tablets. For the generic version, well under $.50 cents per day even at its maximum recommended daily dose. | For the brand name Glucotrol XL, about $90 to $130 for 30 tablets. Generic versions cost about $.15-.25 cents per day. |
| Generic Name | Glimepiride | Glipizide |
| Most Serious Side Effect | Allergic reactions, hypoglycemia, hemolytic anemia (if you have glucose 6-phosphate dehydrogenase deficiency), changes in your vision, loss of consciousness or seizures. | Severe allergic reactions, symptoms of low blood sugar, severe gastrointestinal problems, easy bruising and bleeding, changes in mood. |
| Severe Drug Interactions | Bosentan | Bosentan |
| Typical Dose | 1–8 mg/day, with 1-2 mg/day being sufficient for most people. | 5 mg per day, up to a maximum of 40 mg/day. |
What is Glimepiride?
Glimepiride (also known as Amaryl) and Glipizide are two types of oral anti-diabetic medications belonging to the sulfonylurea class. They were developed after the first generation of this medication, providing a significant improvement in terms of efficacy and safety profile. Both Glimepiride and Glipizide work by stimulating pancreatic beta cells to release insulin, thereby helping to control blood glucose levels in patients with type 2 diabetes.
Glimepiride was approved by the FDA in 1995, several years after Glipizide which was approved in 1984. While both medicines serve similar functions, they do have some differences. Glimepiride has a longer duration action compared to glipizide making it suitable for once-daily dosing. Unlike Prozac's selective serotonin effect with minimal impact on other neurotransmitters, these drugs primarily influence insulin secretion without significantly affecting other hormonal systems.
Both drugs have a good safety profile but like all medications can cause side effects - hypoglycemia being one common concern due to their mechanism of action inducing insulin secretion.
What conditions is Glimepiride approved to treat?
Glimepiride and Glipizide are both approved for the treatment of Type 2 Diabetes Mellitus:
- Glimepiride is utilized as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Glipizide is similarly indicated as an adjunct therapy in conjunction with diet, weight loss, and physical activity for managing type 2 diabetes. It can also be used alongside other antidiabetic medicines when a single medication does not provide adequate blood glucose control.
How does Glimepiride help with these illnesses?
Glimepiride aids in managing type 2 diabetes by stimulating the pancreas to produce more insulin. It does this by binding to and closing potassium channels on beta cells in the pancreas, which results in cell depolarization, opening of calcium channels and influx of calcium. This increase in intracellular calcium leads to insulin release. Insulin is a hormone that allows glucose from the bloodstream into cells where it can be used for energy; its role is crucial for maintaining normal blood sugar levels. Individuals with type 2 diabetes are often resistant to insulin or don't produce enough of it themselves, leading to high blood sugar levels. Therefore, by enhancing insulin production, Glimepiride can reduce hyperglycemia (high blood sugar) effects helping patients manage their condition and stabilize their blood glucose levels.
What is Glipizide?
Glipizide, sold under the brand name Glucotrol among others, is a medication used to treat type 2 diabetes. It works by stimulating the pancreas to release more insulin and facilitating the cells of the body to use this insulin more effectively. It was first approved by FDA in 1984.
Unlike Glimepiride, Glipizide doesn't have an active metabolite which reduces its potential for accumulation or toxicity in patients with decreased kidney function. This makes it a preferred choice for patients who have renal impairment along with their diabetes.
Side effects from taking glipizide may include nausea, diarrhea and upset stomach. However, these side effects are generally mild and temporary; most importantly they do not lead to weight gain or hypoglycemia (low blood sugar levels), as can be common with other drugs used in treatment of type 2 diabetes.
What conditions is Glipizide approved to treat?
Glipizide is an oral medication that has been approved by the FDA for managing blood glucose levels in people with type 2 diabetes. This drug belongs to a class of medications known as sulfonylureas, which work by stimulating the pancreas to produce more insulin. Glipizide can be used:
- As part of a treatment plan when diet and exercise alone does not manage type 2 diabetes effectively
- In combination with other antidiabetic medicines if needed
How does Glipizide help with these illnesses?
Glipizide is a medication that works by stimulating the pancreas to release more insulin, a hormone crucial for regulating blood sugar levels. This drug plays key roles in many processes in the body, affecting how your cells use and store glucose, thus helping to manage symptoms of type 2 diabetes. As with other sulfonylureas such as glimepiride, low levels of insulin can lead to high blood sugar levels or hyperglycemia. Glipizide increases the amount of insulin available in the body, thereby alleviating some symptoms of type 2 diabetes. Its action on pancreatic beta cells may also play roles in its effectiveness against this chronic condition. Since it helps control blood sugar without significantly causing weight gain or hypoglycemia (low blood sugar), it is often prescribed when a patient does not respond well to first-line oral antidiabetic drugs like metformin or along with them for better glycemic control.
How effective are both Glimepiride and Glipizide?
Both glimepiride and glipizide are sulfonylurea drugs that have long been used in the management of type 2 diabetes. Glimepiride was first approved by the FDA in 1995, while glipizide had its initial approval much earlier, in 1984. These medications work to lower blood glucose levels by stimulating pancreatic beta cells to release insulin.
A direct comparison between these two drugs showed similar efficacy in managing symptoms of diabetes. In a double-blind clinical trial conducted in 2001, participants treated with either drug exhibited comparable reductions in HbA1c levels over a period of six months, indicating good glycemic control. There were no significant differences noted across various metrics measuring their effectiveness at controlling blood sugar levels.
Regarding side effects, both medicines can cause hypoglycemia (low blood sugar), but this occurs less frequently with glimepiride compared to other sulfonylureas like glipizide due to its longer duration of action and more specific receptor binding ability.
In terms of dosing regimens, both can be taken once or twice daily depending on individual patient needs and response; however, some studies suggest that patients may experience fewer episodes of hypoglycemia when using a single morning dose regimen for glimepiride rather than split-dose regimens preferred for many other sulfonylureas including glipizide.
A review published in Diabetes Care (2003) suggested that these two drugs perform comparably well against placebo groups and also hold up well when compared directly with each other - making them equally acceptable treatment choices for most patients suffering from Type II Diabetes. However, it's important to note individual healthcare professional opinions may vary based on personal experiences or newer research findings.
Related trials for glimepiride and glipizide
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Glimepiride typically prescribed?
Oral dosages of Glimepiride range from 1–8 mg/day, but studies have indicated that 1-2 mg/day is sufficient for managing type 2 diabetes in most people. Elderly patients may be started on a lower dose to decrease the risk of low blood sugar. In any individual, dosage can be increased after a few weeks if there is no response or if blood glucose levels are not controlled. The maximum dosage that should not be exceeded in any case is 8 mg/day. On the other hand, oral doses of Glipizide range between 5-20mg daily and are usually taken before meals. The starting dose typically ranges from 5–10mg per day; however, it's crucial to monitor closely as the dosage might need adjustment depending on an individual’s blood glucose control.
At what dose is Glipizide typically prescribed?
Glipizide treatment is typically initiated at a dosage of 5 mg per day, taken before breakfast. Depending on the patient's blood sugar levels, this dose can be increased in increments up to a maximum of 40 mg/day, divided into two doses and spaced 12 hours apart if required. This escalation may only be considered if there is no significant response to treatment after several weeks at the initial dosage. The action of glipizide primarily involves stimulating pancreatic β-cells to release insulin; hence it should always be used in conjunction with an appropriate diet and exercise plan for optimal diabetes management.
What are the most common side effects for Glimepiride?
Glimepiride and Glipizide are two medications used to manage blood sugar levels in patients with type 2 diabetes. Common side effects of glimepiride include:
- Nausea
- Vomiting
- Diarrhea or constipation
- Weight gain
- Dizziness, weakness, or headache
- Skin rash
On the other hand, common side effects of glipizide can include:
- Diarrhea
- Gas (flatulence)
- Appetite loss
- Nervousness
- Tremor (unintentional trembling or shaking)
Remember that while these lists provide a range of potential side effects from both drugs, not every individual will experience them and they may often be mild and temporary. However, if you do encounter persistent severe symptoms such as extreme skin reactions, unusual bleeding or bruising, signs of liver problems like yellowing eyes/skin; dark urine; easy bruising/bleeding; persistent nausea/vomiting; abdominal pain — this warrants immediate medical attention.
Are there any potential serious side effects for Glimepiride?
Glimepiride and Glipizide are both oral diabetes medicines that help control blood sugar levels, but they do have potential side effects. Serious side effects may include:
- Allergic reactions: Symptoms such as hives; difficulty breathing or swallowing; swelling of your face, lips, tongue, or throat could indicate an allergic reaction to either medication.
- Hypoglycemia (low blood sugar): Watch for symptoms like sudden sweating, shaking, fast heartbeat, hunger, blurred vision, dizziness or tingling hands/feet.
- Hemolytic anemia (if you have glucose 6-phosphate dehydrogenase deficiency): Look out for signs like pale skin coloration; fatigue; shortness of breath; lightheadedness.
- Changes in your vision: Blurred eyesight is a serious side effect that needs immediate attention.
- Loss of consciousness or seizures: These are severe nervous system reactions and require urgent medical attention.
If you experience any above symptoms after taking these medications please seek immediate medical care. It's important to remember that while this list includes some possible side effects it does not mean everyone will necessarily experience them.
What are the most common side effects for Glipizide?
With Glipizide, some of the potential side effects you may experience include:
- Nausea and loss of appetite
- Diarrhea or constipation
- Dizziness, drowsiness, or headache
- Skin rash or itching
- Weight gain
- Dark urine and yellowing eyes/skin (signs of liver problems)
- Unusual tiredness or weakness These are not all the possible side effects. If any of these persist or worsen, immediate medical attention is required. Also remember that your doctor prescribed this medication because they judged that the benefit to you is greater than the risk of side effects.
Are there any potential serious side effects for Glipizide?
Glipizide is generally well-tolerated, but in some cases, it can cause serious side effects. If you notice any of the following symptoms while taking Glipizide, seek medical help immediately:
- Signs of severe allergic reaction like skin rash or hives; itching; redness, swelling or peeling with blistering of your skin; swollen glands; difficulty in breathing; sudden swelling on your face, lips, tongue or throat
- Symptoms that could indicate low blood sugar: confusion, dizziness or lightheadedness, pounding heartbeat or irregular pulse rate
- Severe gastrointestinal problems: dark urine and light stools change from normal color to a yellowish tinge
- Easy bruising and bleeding indicating changes in blood cell counts
- Changes in mood such as feeling anxious, restless or depressed which may lead to suicidal thoughts.
It's crucial to remember these are not all the possible side effects linked with Glipizide. Always consult your doctor if you experience unusual symptoms after starting this medication.
Contraindications for Glimepiride and Glipizide?
Both glimepiride and glipizide, as with most other drugs for managing diabetes, may cause hypoglycemia (low blood sugar) in some individuals. If you notice symptoms of hypoglycemia such as sudden sweating, shaking, fast heartbeat or blurred vision, seek medical attention immediately.
Neither glimepiride nor glipizide should be used if you are taking bosentan. Always inform your doctor about all the medications you are currently using; bosentan will require a period of at least 5 weeks to clear from your system before starting on either glimepiride or glipizide to prevent harmful interactions.
Furthermore, these medications should not be used by patients with diabetic ketoacidosis or those allergic to sulfonylureas. Before starting treatment with either drug, it's crucial that you let your healthcare provider know about any existing liver or kidney disease.
How much do Glimepiride and Glipizide cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Glucotrol XL (glipizide extended-release, 5 mg) averages around $90 to $130. This works out to approximately $3 to $4/day depending on your dose.
- The price of 30 tablets for Amaryl (glimepiride, 2 mg) ranges from about $125 to $170, which equates to approximately between a range of significantly more than glipizide at roughly about $4–6/day.
Therefore, if you are in a higher dosage range for Glimepiride (i.e., up-to 8mg per day), then brand-name Glucotrol XL could prove less expensive on a per-day treatment basis. However, please note that cost should not be your primary consideration in determining which drug is right for you.
For the generic versions of glimepiride and glipizide, costs are significantly lower:
-
Generic glipizide is available in packs starting with counts as low as 30 tablets with costs ranging from about $.15-.25 cents per day at doses such as 5 or even up-to10 mg daily.
-
Similarly priced when considering larger quantities purchased upfront; generic glimepiride's cost also falls in an affordable range with prices varying based on factors like quantity obtained and location but generally falling well under $.50 cents per day even at its maximum recommended daily dose.
Popularity of Glimepiride and Glipizide
Glimepiride, available under the brand name Amaryl among others, was estimated to have been prescribed to about 8.3 million people in the US in 2020. Glimepiride accounted for just over 15% of sulfonylurea prescriptions in the US. As a second-generation sulfonylurea, glimepiride is used for managing blood sugar levels in people with type 2 diabetes and has seen a steady increase since its introduction.
Glipizide, sold under various brand names including Glucotrol among others, was prescribed to around 6 million people in the USA during that same period. In terms of sulfonylurea prescriptions across America, glipizide accounts for approximately 13%. The prevalence of glipizide has remained stable over recent years due to its continued effectiveness as an oral hypoglycemic medication. Both medications are critical tools in managing type-2 diabetes but should be chosen carefully based on individual patient needs and potential side effects.
Conclusion
Both Glimepiride and Glipizide have extensive records of usage in patients with type 2 diabetes, supported by numerous clinical studies indicating their efficacy over placebo treatments. They are both sulfonylureas that work to control blood sugar levels by stimulating the pancreas to produce more insulin. At times, they may be used together under careful supervision from a healthcare provider.
Glimepiride is usually taken once a day with breakfast or the first main meal of the day, while glipizide can be taken either once or twice daily thirty minutes before meals.
Both drugs are available in generic form which represents significant cost savings for patients who must pay out-of-pocket. The effects of these drugs may not always be noticeable right away as it takes time for them to lower blood glucose levels effectively.
Side effects common to both include hypoglycemia (low blood sugar), headache, nausea, dizziness and weight gain. However, glimepiride has been linked less frequently with inducing episodes of hypoglycemia compared to glipizide. Both medications require close monitoring especially when initiating therapy or adjusting doses because they can cause severe low blood sugar if not managed correctly. Patients should seek medical help immediately if they experience symptoms such as persistent nausea/vomiting, stomach/abdominal pain, dark urine or yellowing eyes/skin which might indicate liver disease - though this is rare.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Campbell, R. K. (1998, October). Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy. SAGE Publications.http://doi.org/10.1345/aph.17360
- Gregorio, F., Ambrosi, F., Cristallini, S., Filipponi, P., & Santeusanio, F. (1996). Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetologica. Springer Science and Business Media LLC.http://doi.org/10.1007/bf00571936
- Lebovitz, H. E. (1985, March 4). Glipizide: A Second‐generation Sulfonylurea Hypoglycemic Agent; Pharmacology, Pharmacokinetics and Clinical Use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Wiley.http://doi.org/10.1002/j.1875-9114.1985.tb03405.x
- Brogden, R. N., Heel, R. C., Pakes, G. E., Speight, T. M., & Avery, G. S. (1979, November). Glipizide. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-197918050-00001
- Umayahara, R., Yonemoto, T., Kyou, C., Morishita, K., Ogawa, T., Taguchi, Y., & Inoue, T. (2014). Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocrine Journal. Japan Endocrine Society.http://doi.org/10.1507/endocrj.ej14-0233
- Carroll, M. F., Gutierrez, A., Castro, M., Tsewang, D., & Schade, D. S. (2003, November 1). Targeting Postprandial Hyperglycemia: A Comparative Study of Insulinotropic Agents in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society.http://doi.org/10.1210/jc.2003-030649
- Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., … for the LEAD-2 Study Group. (2009, January 1). Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc08-1355
- Douros, A., Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2017, September 1). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc17-0595
- Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group. (2007, June 26). Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity and Metabolism. Wiley.http://doi.org/10.1111/j.1463-1326.2007.00744.x
- Langtry, H. D., & Balfour, J. A. (1998). Glimepiride. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-199855040-00007
- Dills, D., & Schneider, J. (1996, September). Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study. Hormone and Metabolic Research. Georg Thieme Verlag KG.http://doi.org/10.1055/s-2007-979831